DTx Pharma Appoints Michael Huang, MD as Chief Medical Officer | Business and finance


DTx Pharma, Inc. (DTx), a California-based private biotechnology company developing novel RNA-based therapies to address genetic drivers of disease, today announced the appointment of Dr. Michael Huang as Chief Medical Officer. Dr. Huang will provide leadership and oversight of DTx Pharma’s pipeline of clinical development programs.

“We are delighted to welcome Dr. Huang to DTx Pharma at this pivotal moment in our evolution. His caliber as a leader and his extensive experience building effective teams for biotech companies will be invaluable as we continue to advance our pipeline,” said Arthur T. Suckow, co-founder and CEO of DTx. Pharmaceuticals.

With extensive leadership experience in advancing drug candidates through all phases of clinical development, his contributions have led to marketing approvals for numerous treatments including Potiga®, Zevalin®, Uceris®, Ruconest ® and Austedo®.

Prior to DTx Pharma, Dr. Huang held key leadership positions at AmMax Bio and Spruce Biosciences. During his career, he has led programs in RNA, biologics and small molecule therapeutics from initial IND to clinical proof of concept, late-stage development and beyond. of the. Dr. Huang has also been recognized for successfully supporting fundraising and business development activities. He is also the author of a multitude of peer-reviewed journal articles, abstracts and scientific publications.

Dr. Huang holds a Bachelor of Science in Molecular and Cellular Biology from the University of California, Berkeley and received his medical degree from Chicago Medical School.

“What DTx Pharma has built is truly unique and incredibly valuable,” Dr. Huang said. “The team has created an impressive platform to help patients with genetic diseases. I am both thrilled and grateful to join the team’s journey to ensure that we can treat countless disease targets that are currently incurable due to pathogenic genes.

DTx Pharma, Inc. is a privately held, clinical-stage biotechnology company tackling the challenges associated with treating genetic diseases by leveraging RNA-based therapies. The Company’s proprietary delivery technology platform uses fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad oligonucleotide activity in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform to and into clinical development, DTx has raised over $100 million in combined investments from several of the world’s leading healthcare investors, including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.



Copyright BusinessWire 2022.

PUBLICATION: 05/31/2022 07:30 / DISK: 05/31/2022 07:32

Copyright BusinessWire 2022.